S100P：癌症的一个新治疗靶点。
S100P: a novel therapeutic target for cancer.
机构信息
Department of Cancer Biology, UT MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA.
出版信息
Amino Acids. 2011 Oct;41(4):893-9. doi: 10.1007/s00726-010-0496-4. Epub 2010 May 28.
S100P expression is described in many different cancers, and its expression is associated with drug resistance, metastasis, and poor clinical outcome. S100P is member of the S100 family of small calcium-binding proteins that have been reported to have either intracellular or extracellular functions, or both. Extracellular S100P can bind with the receptor for advanced glycation end products (RAGE) and activate cellular signaling. Through RAGE, S100P has been shown to mediate tumor growth, drug resistance, and metastasis. S100P is specifically expressed in cancer cells in the adult. Therefore, S100P is a useful marker for differentiating cancer cells from normal cells, and can aid in the diagnosis of cancer by cytological examination. The expression of S100P in cancer cells has been related to hypomethylation of the gene. Multiple studies have confirmed the beneficial effects of blocking S100P/RAGE in cancer cells, and different blockers are being developed including small molecules and antagonist peptides. This review summarizes the role and significance of S100P in different cancers.
S100P 在许多不同的癌症中都有表达，其表达与耐药性、转移和不良临床结局有关。S100P 是 S100 家族中小的钙结合蛋白成员，据报道具有细胞内或细胞外功能，或兼有两者。细胞外 S100P 可以与晚期糖基化终产物受体（RAGE）结合并激活细胞信号转导。通过 RAGE，S100P 已被证明可介导肿瘤生长、耐药和转移。S100P 仅在成体的癌细胞中特异性表达。因此，S100P 是区分癌细胞和正常细胞的有用标志物，通过细胞学检查有助于癌症的诊断。癌细胞中 S100P 的表达与基因的低甲基化有关。多项研究证实了阻断癌细胞中 S100P/RAGE 的有益作用，并且正在开发包括小分子和拮抗剂肽在内的不同阻断剂。这篇综述总结了 S100P 在不同癌症中的作用和意义。
Zotero 插件